From the outset of his career, Lim understood that for research to make an impact, it needs to be translated from the laboratory to the bedside.

This is where he makes the greatest contribution by leveraging on his basic research outcomes and his expertise in engineering to develop a new generation of biomedical technologies for better disease diagnosis, prognosis and precision therapy.

This patented technology is simple and easy to use, providing a next generation of non-invasive 'liquid biopsy' devices for cancer diagnosis.

[19] The key innovation involved cancer cells being captured and analysed from a routine blood draw rather than through the painful route of needle aspiration tumour biopsy.

Lim was the Founding Director of the Singapore Health Technologies Consortium (HealthTEC.SG) which comprises a network of over 70 health and medical technology companies[26] with the aim of promoting closer research collaboration and quicker transfer of knowledge and research outcomes from academia to industry.